{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:10:16Z","timestamp":1784607016200,"version":"3.55.0"},"reference-count":66,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T00:00:00Z","timestamp":1366070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:p>As a consequence of inhibition of the hepatic cytochrome <jats:styled-content style=\"fixed-case\">P450 3A4<\/jats:styled-content> isozyme, treatment with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> protease inhibitors can result in significant drug\u2212drug interactions. One noteworthy interaction is between protease inhibitors and inhaled or intranasal corticosteroids. This interaction can result in adrenal insufficiency and iatrogenic <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>ushing's syndrome (with symptoms such as rapid weight gain, obesity, facial hirsutism and swelling), as well as hypertension, osteoporosis and decreased <jats:styled-content style=\"fixed-case\">CD4<\/jats:styled-content> cell count. In this paper, we review and unite pharmacokinetic data, case reports and current research regarding this drug\u2212drug interaction in order to suggest options for the clinical management of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u2010positive patients requiring treatment with protease inhibitors and inhaled or intranasal corticosteroids.<\/jats:p>","DOI":"10.1111\/hiv.12039","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T03:14:24Z","timestamp":1366168464000},"page":"519-529","source":"Crossref","is-referenced-by-count":64,"title":["Inhaled corticosteroid use in <scp>HIV<\/scp>\u2010positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management"],"prefix":"10.1111","volume":"14","author":[{"given":"P","family":"Saberi","sequence":"first","affiliation":[{"name":"Department of Medicine University of California  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Phengrasamy","sequence":"additional","affiliation":[{"name":"Kaiser Permanente  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DP","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Kaiser Permanente  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,16]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Norvir Package Insert","author":"AbbVie, Inc.","year":"2013"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200403-025MS"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000026349"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023010-00002"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0039-128X(94)90054-X"},{"key":"e_1_2_6_7_1","volume-title":"Flovent HFA Package Insert","author":"GlaxoSmithKline","year":"2012"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80113-2"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000242929.95258.69"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.3848"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0653-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K075"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.11.034"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2011.606580"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2006.0117"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328013d9c7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000166102.21391.81"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/1545109709332019"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199909100-00038"},{"key":"e_1_2_6_20_1","first-page":"274","article-title":"Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone","volume":"75","author":"Chen F","year":"1999","journal-title":"Sex Transm Infect"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0928"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/02770903.2010.485666"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1081\/JAS-200038366"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0036"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00149.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/342562"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1179\/ACB.67.2.2062641"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2001.00058.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2011.011408"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1297993"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP09288.CR"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2004.00723.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2009.009339"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.12.057"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00579.x"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2005.01.013"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000187444.38461.70"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7539.469"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.014"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31824ceb2b"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.18021.x"},{"key":"e_1_2_6_42_1","first-page":"16","article-title":"Cushing syndrome secondary to topical glucocorticoids","volume":"9","author":"Joe EK","year":"2003","journal-title":"Dermatol Online J"},{"key":"e_1_2_6_43_1","unstructured":"Okasaki\u2010GutierrezR PooleP Troia\u2010ConcioP AsmuthDM eds.Prevalence of subclinical iatrogenic cushing's syndrome (ICS) in patients being co\u2010administered ritonavir and corticosteroids via inhaled intranasal and\/or topical route.XIX International AIDS Conference. Washington DC 2012[Poster #MOPE103]."},{"key":"e_1_2_6_44_1","unstructured":"BoydS HadiganC PauAet\u2009al. eds.DRV\/r Does Not Significantly Increase Plasma Concentrations of Orally Inhaled Beclomethasone in Healthy Volunteers.19th Conference on Retroviruses and Opportunistic Infections. Seattle WA 2012[Poster #611]."},{"key":"e_1_2_6_45_1","unstructured":"BoydS PenzakS NiemanLet\u2009al. eds.Coadministration of Orally Inhaled Beclomethasone and HIV Protease Inhibitors Does Not Significantly Alter Adrenal Function in Healthy Volunteers.19th Conference on Retroviruses and Opportunistic Infections. Seattle WA 2012[Poster #610]."},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(98)90434-6"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20049"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-8-54"},{"key":"e_1_2_6_49_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1465-9921-5-7","article-title":"Significant receptor affinities of metabolites and a degradation product of mometasone furoate","volume":"5","author":"Valotis A","year":"2004","journal-title":"Respir Res"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq1126"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01374.x"},{"key":"e_1_2_6_52_1","first-page":"86","article-title":"Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid","volume":"122","author":"Ryrfeldt A","year":"1982","journal-title":"Eur J Respir Dis Suppl"},{"key":"e_1_2_6_53_1","volume-title":"Product Information","author":"Rhinocort AQ","year":"2010"},{"key":"e_1_2_6_54_1","volume-title":"Flexhaler Prescribing Information","author":"Pulmicort","year":"2010"},{"key":"e_1_2_6_55_1","volume-title":"Prescribing Information","author":"Omnaris","year":"2010"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.54"},{"key":"e_1_2_6_57_1","volume-title":"Prescribing Information","author":"Veramyst","year":"2011"},{"key":"e_1_2_6_58_1","volume-title":"Prescribing Information","author":"Flovent HFA","year":"2010"},{"key":"e_1_2_6_59_1","volume-title":"Prescribing Information","author":"Nasonex","year":"2012"},{"key":"e_1_2_6_60_1","volume-title":"Prescribing Information","author":"Asmanex Twisthaler","year":"2012"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008335"},{"key":"e_1_2_6_62_1","volume-title":"Product Information","author":"QVAR","year":"2012"},{"issue":"4","key":"e_1_2_6_63_1","first-page":"11","article-title":"Metabolism of beclomethasone dipropionate by animals and man","volume":"51","author":"Martin LE","year":"1975","journal-title":"Postgrad Med J"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022137"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022009413"},{"key":"e_1_2_6_66_1","volume-title":"Prescribing Information","author":"Nasacort AQ","year":"2010"},{"key":"e_1_2_6_67_1","volume-title":"Prescribing Information","author":"Beconase AQ","year":"2005"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12039","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:24:23Z","timestamp":1696321463000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,16]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/hiv.12039"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12039","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,16]]}}}